Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer
Autore:
Kasimis, B; Wilding, G; Kreis, W; Feuerman, M; Chang, V; Hwang, S; Steafather, H; Cogswell, J; Rae, C; Blumenfrucht, M;
Indirizzi:
Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Vet Affairs, New Jersey Hlth Care Syst,Sect Hematol Oncol, Newark, NJ USA Univ Med & Dent New Jersey Newark NJ USA t Hematol Oncol, Newark, NJ USA Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA Univ Wisconsin Madison WI USA nsin, Ctr Comprehens Canc, Madison, WI USA Cornell Univ, Coll Med, N Shore Univ Hosp, Manhasset, NY USA Cornell UnivManhasset NY USA Med, N Shore Univ Hosp, Manhasset, NY USA Univ Med & Dent New Jersey, New Jersey Med Sch, IST Acad Comp Serv, Newark, NJ USA Univ Med & Dent New Jersey Newark NJ USA Acad Comp Serv, Newark, NJ USA
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 7, volume: 18, anno: 2000,
pagine: 602 - 608
SICI:
0735-7907(2000)18:7<602:SOPWHS>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
WITHDRAWAL SYNDROME; ENDOCRINE THERAPY; RANDOMIZED TRIAL; CLINICAL-TRIALS; CARCINOMA; FLUTAMIDE; CHEMOTHERAPY; EXPERIENCE; ORCHIECTOMY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Kasimis, B DVA, NJ Hlth Care Syst, Sect Hematol Oncol 111, 385 Tremont Ave, E Orange,NJ 07018 USA DVA 385 Tremont Ave E Orange NJ USA 07018 E Orange,NJ 07018 USA
Citazione:
B. Kasimis et al., "Survival of patients who had salvage castration after failure on bicalutamide monotherapy for stage (D-2) prostate cancer", CANCER INV, 18(7), 2000, pp. 602-608

Abstract

Patients with hormone-naive stage D-2 prostate cancer often benefit from castration. This treatment, however, frequently produces many unacceptable physical and psychological side effects, especially in younger and sexually active patients. Bicalutamide is an oral antiandrogen with excellent tolerance and preservation of sexual function. Three institutions participated inphase II and III trials of bicalutamide monotherapy (50 mg daily) as primary therapy in hormone-naive patients with stage D-2 prostate cancer. Upon bicalutamide failure, all patients underwent castration and were followed until death. Fifty-four patients received bicalutamide 50 mg orally once a day. One patient (2%) had complete response, 9 patients (17%) had partial response, and 27 patients (50%) had stable disease. Seventeen patients (31%) had progressive disease. The median time to bicalutamide failure was 47.4 weeks, 70.5 weeks for the responders vs. 25.4 weeks for the nonresponders (p < 0.001). The median survival time after the sequential use of bicalutamideand castration was 119.2 weeks for all 54 patients, 162.0 weeks for the responders, and 73.5 weeks for nonresponders (p < 0.0001). The median survival time after initiation of castration was 71.1 weeks for all 54 patients, 91.4 weeks for bicalutamide responders, and 42.1 weeks for nonresponders (p < 0.01). In hormone-naive patients with stage D-2 prostate cancer, sequential treatment with bicalutamide monotherapy followed by castration upon failure may produce survival time within the range reported for initial treatment with castration. Thus, considering the favorable quality of life profileof bicalutamide, further studies are needed to define the role of sequential hormonal therapy in younger sexually active patients.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 10/07/20 alle ore 11:58:07